Literature DB >> 12969979

Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation.

Katja Brocke-Heidrich1, Antje K Kretzschmar, Gabriele Pfeifer, Christian Henze, Dennis Löffler, Dirk Koczan, Hans-Jürgen Thiesen, Renate Burger, Martin Gramatzki, Friedemann Horn.   

Abstract

Interleukin 6 (IL-6) is a growth and survival factor for multiple myeloma cells. As we report here, the IL-6-dependent human myeloma cell line INA-6 responds with a remarkably rapid and complete apoptosis to cytokine withdrawal. Among the antiapoptotic members of the B-cell lymphoma-2 (Bcl-2) family of apoptosis regulators, only myeloid cell factor-1 (Mcl-1) was slightly induced by IL-6. Overexpression studies demonstrated, however, that IL-6 does not exert its survival effect primarily through this pathway. The IL-6 signal transduction pathways required for survival and the target genes controlled by them were analyzed by using mutated receptor chimeras. The activation of signal transducer and activator of transcription 3 (Stat3) turned out to be obligatory for the survival of INA-6 cells. The same held true for survival and growth of XG-1 myeloma cells. Gene expression profiling of INA-6 cells by using oligonucleotide microarrays revealed many novel IL-6 target genes, among them several genes coding for transcriptional regulators involved in B-lymphocyte differentiation as well as for growth factors and receptors potentially implicated in autocrine or paracrine growth control. Regulation of most IL-6 target genes required the activation of Stat3, underscoring its central role for IL-6 signal transduction. Taken together, our data provide evidence for the existence of an as yet unknown Stat3-dependent survival pathway in myeloma cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12969979     DOI: 10.1182/blood-2003-04-1048

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

1.  HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines.

Authors:  Paul A Johnston; Malabika Sen; Yun Hua; Daniel P Camarco; Tong Ying Shun; John S Lazo; Gabriela Mustata Wilson; Lynn O Resnick; Matthew G LaPorte; Peter Wipf; Donna M Huryn; Jennifer R Grandis
Journal:  Assay Drug Dev Technol       Date:  2015-09       Impact factor: 1.738

Review 2.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

Review 3.  Interleukin-6 in aging and chronic disease: a magnificent pathway.

Authors:  Marcello Maggio; Jack M Guralnik; Dan L Longo; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2006-06       Impact factor: 6.053

4.  Down-regulated G protein-coupled receptor kinase 6 leads to apoptosis in multiple myeloma MM1R cells.

Authors:  Zhiyao Zhang; Zhenyu Li; Wenming Chen
Journal:  Exp Ther Med       Date:  2018-09-11       Impact factor: 2.447

5.  Bone marrow-derived mesenchymal stromal cells promote survival and drug resistance in tumor cells.

Authors:  Scott A Bergfeld; Laurence Blavier; Yves A DeClerck
Journal:  Mol Cancer Ther       Date:  2014-02-06       Impact factor: 6.261

6.  Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.

Authors:  Rakesh Bam; Wen Ling; Sharmin Khan; Angela Pennisi; Sathisha Upparahalli Venkateshaiah; Xin Li; Frits van Rhee; Saad Usmani; Bart Barlogie; John Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Am J Hematol       Date:  2013-03-28       Impact factor: 10.047

7.  Activated STAT3 is a mediator and biomarker of VEGF endothelial activation.

Authors:  Shao-Hua Chen; Danielle A Murphy; Wiem Lassoued; Gavin Thurston; Michael D Feldman; William M F Lee
Journal:  Cancer Biol Ther       Date:  2008-12-11       Impact factor: 4.742

Review 8.  Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells.

Authors:  Fatemeh Norozi; Ahmad Ahmadzadeh; Saeid Shahrabi; Tina Vosoughi; Najmaldin Saki
Journal:  Tumour Biol       Date:  2016-07-20

9.  Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells.

Authors:  Shadia Zaman; Rui Wang; Varsha Gandhi
Journal:  Exp Hematol       Date:  2015-08-06       Impact factor: 3.084

10.  High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis.

Authors:  Anne-Tove Brenne; Unn-Merete Fagerli; John D Shaughnessy; Thea Kristin Våtsveen; Torstein Baade Rø; Hanne Hella; Fenghuang Zhan; Bart Barlogie; Anders Sundan; Magne Børset; Anders Waage
Journal:  Eur J Haematol       Date:  2009-01-13       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.